

Drawing AMENDMENTS

There are no amendments to the drawings.

REMARKS

The following claims are pending in the application: 1 – 33

The following claims have been amended: 13(a) and 13(b)

The following claims have been deleted or
withdrawn: 16 – 33

The following claims have been added: N/A

As a result of the foregoing Amendment, the following claims remain pending in the application: 1 – 15.

Election/Restriction Requirement

The Examiner has required restriction of the claims between five groups of claims:

Group I including claims 1 – 15 drawn to a method of treating diabetes in a human;

Group II including claim 16 drawn to a pharmaceutical composition for suppressing or reducing the immune response;

Group III including claims 17 - 29 drawn to a method to increase insulin production in a diabetes patient with beta cell antibodies;

Group IV including claims 30 – 31 drawn to a method to treat beta cell inflammation; and

Group V including claims 32 – 33 drawn to a pharmaceutical composition for the treatment of diabetes.

In response, Applicants hereby elect to prosecute the claims drawn to a method of treating diabetes in humans, which are covered by claims 1 – 15. Applicants' election is without traverse.

Application No. 10/804,845

Applicants acknowledge the error in the initial numbering of the claims and thank the Examiner for pointing out the error. Applicants have renumbered such claims as suggested by the Examiner. Aside from the renumbering of the two claims originally numbered 13, no other changes to these two claims were made.

Applicants respectfully request that the Examiner enter the following Amendment and consider the following Remarks. Applicants respectfully request that the Examiner reconsider and again examine the present application and claims in light thereof.

CONCLUSION

In view of the foregoing amendment and accompanying remarks, the Applicants respectfully submit that the present application is properly in condition for allowance and may be passed to issuance upon payment of the appropriate fees.


Telephone inquiry to the undersigned in order to clarify or otherwise expedite prosecution of the subject application is respectfully encouraged.

Respectfully submitted,

Date:

May 5, 2006

By:



Roger A. Gilcrest, Registration No.: 31,954

Schottenstein, Zox & Dunn Co., L.P.A.

250 West Street

Columbus, Ohio 43215

Mailing Address:

P.O. Box 165020

Columbus, Ohio 43216-5020

P: (614) 462-1055

F: (614) 222-3437

Email: rgilcrest@szd.com